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Edited by Sandro SonninoAbstract The action of antibacterial cathelicidin peptide
CAP11 on the anandamide production from mononuclear phago-
cytes was examined. Lipopolysaccharide (LPS)-stimulation
induced the anandamide production from macrophage-like
RAW264.7, accompanied with the enhanced anandamide-synthe-
sizing enzyme activity; however, the anandamide-degrading
enzyme activity was not changed by LPS-stimulation. Impor-
tantly, CAP11 suppressed the LPS-induced anandamide produc-
tion and the increase of anandamide-synthesizing enzyme
activity. Furthermore, CAP11 abrogated the LPS-binding to
CD14-positive RAW264.7. These observations indicate that
CAP11 inhibits the binding of LPS to CD14-positive mononu-
clear phagocytes, thereby suppressing the anandamide synthesiz-
ing enzyme activity and the anandamide production from the
cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lipopolysaccharide (LPS), also called endotoxin is a major
component of the outer membrane of Gram-negative bacteria,
and is the most potent activator of mononuclear phagocytes
(macrophage and monocyte). LPS triggers mononuclear
phagocytes to secrete TNF-a, IL-1b, IL-6 and other mediators
such as endogenous cannabinoids, a new class of lipid media-
tors [1,2]. Anandamide is one of the potent agonists for
cannabinoid receptor [3,4]. Anandamide induces the character-
istic blood pressure response that leads to hypotension andAbbreviations: LPS, lipopolysaccharide; CAP11, cationic antibacterial
peptide of 11-kDa; NAPE-PLD, N-arachidonyl phosphatidylethanol-
amine hydrolyzing phospholipase D; FAAH, fatty acid amide
hydrolase; FCS, fetal calf serum; DBD-COCL, 4-(N,N-di-
methylaminosulfonyl)-7-(N-chloroformylmethyl-N-methylamino)-2,1,3-
benzoxadiazole; RT-PCR, reverse transcription-polymerase chain
reaction
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doi:10.1016/j.febslet.2006.12.017often bradycardia, via a cannabinoid CB1 receptor and a
vanilloid TRPV1 (transient receptor potential vanilloid 1)
receptor [5,6]. Thus, anandamide is regarded as a key compo-
nent that plays a role in the pathoformic stage of Gram-nega-
tive bacterial endotoxin shock [2].
To date, several strategies including neutralizing antibodies
of LPS, cytokines, and other related signal molecules have
been tested to regulate the signal cascade of endotoxin shock
[7,8]. Among these, much attention has focused on the low-
molecule-weight cationic antibacterial polypeptides that pos-
sess both the antibacterial and LPS-neutralizing activities [9–
11]. The peptide-based defense against microbial invasion is
comprised of two distinct groups of antimicrobial peptides,
cathelicidins and defensins, which have been identiﬁed in sev-
eral epithelial tissues and in the granules of phagocyte
[12,13]. Previously, we isolated CAP11 (cationic antibacterial
polypeptide of 11-kDa), an a-helical cathelicidin peptide, from
guinea pig neutrophils, and revealed that CAP11 has the po-
tent abilities to not only kill Gram-positive and -negative bac-
teria but also neutralize LPS; CAP11 can inhibit the binding of
LPS to CD14-positive cells and protect mice from endotoxin
shock [11,14–16]. Thus, it could be hypothesized that CAP11
may regulate the production of anandamide, a key inducer
for endotoxin shock, from mononuclear phagocytes by aﬀect-
ing the LPS-binding to the cells. In this study, to evaluate the
eﬀect of CAP11 on anandamide production, we measured the
anandamide production, and the activities for anandamide-
producing enzyme and -degrading enzyme in mononuclear
phagocytes stimulated with LPS in the absence or presence
of CAP11, using a murine macrophage cell line RAW264.7.2. Materials and methods
2.1. Materials
Anandamide was purchased from Cayman Chemicals (Ann Arbor,
MI, USA); N-arachidonyl phosphatidylethanolamine was from Bio-
mol International, L.P. (Plymouth Meeting, PA, USA); [ethanolamine
1-3H] anandamide and [arachidonyl-5,6,8,9,11,12,14,15-3H] N-arachi-
donyl phosphatidylethanolamine were from American Radiolabeled
Chemicals, Inc. (St. Louis, MO, USA): 4-(N,N-dimethylaminosulfonyl)-
7-(N-chloroformylmethyl-N-methylamino)-2,1, 3-benzoxadiazole (DBD-
COCL) was from Tokyo Chemical Industry (Tokyo, Japan): lipopoly-
saccharide (LPS, E. coli O111:B4) was from Sigma Chemical Co.,
(St. Louis); Alexa Fluor-488 conjugated LPS was from Molecularblished by Elsevier B.V. All rights reserved.
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(G1LRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQI-
PYPCRI43) were synthesized by a solid phase method on a peptide
synthesizer (model PSSM-8; Shimadzu, Kyoto, Japan) by ﬂuorenyl-
methoxycarbonyl chemistry, and puriﬁed, as described previously
[11,14–16]. A neutralizing anti-CD14 monoclonal antibody (4C1)
was kindly provided by Dr. Adachi (Tokyo University of Pharmacy
and Life Science, Japan) [17].
2.2. Extraction and derivatization of anandamide
RAW264.7 cells were maintained in RPMI1640 (Sigma) containing
10% fetal calf serum (FCS; <0.03 ng/ml endotoxin, Equitech-Bio,
Kerrville, TX, USA). RAW264.7 (80–90% conﬂuent in 150 mm dish)
were washed with serum-free medium, and incubated without or with
LPS (10 ng/ml) in the absence or presence of CAP11 (100 and 1000 ng/
ml) in RPMI1640 containing 2% FCS at 37 C for 2 h. The cells and
media were recovered, and immediately added with phenymethylsulfo-
nyl ﬂuoride (an inhibitor for anandamide-degrading enzyme, fatty acid
amide hydrolase) at a ﬁnal concentration of 100 lM. Extraction of
anandamide was carried out with chloroform and methanol, according
to Bligh and Dyer’s method [18]. After centrifugation at 1000 · g for
10 min, the organic phase containing total lipid was collected and dried
by nitrogen gas stream. The residue was reconstituted in 100 ll aceto-
nitrile, and subjected to reverse-phase HPLC using a JASCO System
equipped with an TSK gel ODS 80Ts (75 · 4.6 mm; Tosoh, Tokyo,
Japan) column and a UV detector (JASCO, Tokyo, Japan). Anandamide
was separated with an isocratic elution solvent consisted of acetonitrile
and water (8:2, v/v). The fractions corresponding to the elution time of
authentic anandamide were collected, dried with nitrogen stream, and
reconstituted in 50 ll acetonitrile. The anandamide-containing solu-
tion was then added with 50 ll of 10 mM DBD-COCL, and vortexed
thoroughly, followed by heating at 60 C for 2 h for derivatization.
Derivatization was stopped by adding 100 ll water, and then the mix-
ture was subjected to solid phase extraction using a Empore C-18 disk
cartridge column (Sumitomo 3 M, Tokyo, Japan) preconditioned by
200 ll acetonitrile and 400 ll water. Then, the column was washed
twice with 150 ll acetonitrile/water (40/60, v/v), and the derivatized
anandamide was eluted with 200 ll acetonitrile/water (90/10, v/v).
The aliquot (40 ll) was subjected to HPLC analysis for the quantiﬁca-
tion of anandamide [19].
2.3. Quantiﬁcation of anandamide by HPLC
The HPLC system consisted of an L-2180 pump, an L-2480 ﬂuores-
cence detector, a D-2500 integrator (Hitachi, Tokyo, Japan), and an
analytical column TSK-gel ODS 80Ts (75 · 4.6 mm) (Tosho, Tokyo,
Japan). Separation was performed with a gradient using the two elu-
ents A (acetonitrile/water, 70/30, v/v) and B (acetonitrile); 0–5 min, iso-
cratic 100% A; 5–35 min, a liner gradient from 100% to 33% of A and
0% to 67% B; 35–40 min, a liner gradient from 33% to 0% A and 67%
to 100% B; 40–50 min, isocratic at 100% B; 50–60 min, a liner gradient
from 0% to 100% A and 100% to 0% B.
2.4. Subcellular fractionation
RAW264.7 cells (80–90% conﬂuent in 150 mm dish) were incubated
without or with LPS (10 ng/ml) in the absence or presence of CAP11
(100 and 1000 ng/ml) in RPMI1640 containing 10% FCS at 37 C
for 2 h. To prepare membrane fraction containing anandamide-synthe-
sizing and -degrading enzymes, subcellular fractionation was per-
formed [20,21]. In brief, after the incubation, cells were washed,
suspended in 1 ml of 50 mM Tris–HCl (pH 7.3) containing 0.25 M su-
crose and 0.05% EDTA, and sonicated on ice (50 W, 10 s). Cell debris
were pelleted by centrifugation at 1000 · g for 5 min at 4 C, and the
supernatants were further centrifuged at 105000 · g for 1 h. Resulting
pellets (membrane fractions containing enzyme samples) were resus-
pended in 60 mM bis-Tris–propane (pH 8.0) containing 2 mM dithio-
threitol, 0.1% Triton X-100 and 10 mM CaCl2 for the assay of
anandamide-synthesizing enzyme, and 50 mM Tris–HCl (pH 9.0) con-
taining 1 mM EDTA for anandamide-degrading enzyme, respectively.
The protein contents were determined with the DC Protein Assay
regents (Bio-Rad, Hercules, CA, USA).
2.5. Assay for the anandamide-synthesizing enzyme activity
The anandamide-synthesizing enzyme activity was measured as de-
scribed previously [20]. Membrane fractions (100 lg protein) weremixed with a substrate, [3H] N-arachidonyl phosphatidylethanolamine
(NAPE; 100 lM, 12000 dpm/nmol) in a total volume of 100 ll 60 mM
bis-Tris–propane (pH 8.0) containing 2 mM dithiothreitol, 0.1% Tri-
ton X-100 and 10 mM CaCl2, and incubated at 37 C for 30 min.
The reaction was stopped by the addition of 250 ll ice-cold methanol,
and unreacted NAPE was precipitated for 15 min after the addition of
50 ll 0.2 M ZrCl2–0.1 M NaOH and 75 ll 0.1 M NaH2PO4. There-
after, the mixtures were centrifuged at 5000 · g for 15 min, and
aliquots of the supernatants (200 ll) were subjected to liquid scintilla-
tion counting.
2.6. Assay for the mRNA expression of N-arachidonyl phosphatidyl-
ethanolamine hydrolyzing phospholipase D (NAPE-PLD)
RAW264.7 cells (80–90% conﬂuent in 150 mm dish) were incubated
without or with LPS (10 ng/ml) in the absence or presence of
CAP11 (100 and 1000 ng/ml) in RPMI1640 containing 10% FCS at
37 C for 2 h. Thereafter, total RNA was extracted, and the expression
of NAPE-PLD and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA was analyzed by reverse transcription-polymerase
chain reaction (RT-PCR). In brief, total RNA was puriﬁed using an
RNeasy mini kit (Qiagen, Valencia, CA), and RT-PCR was performed
using a ReverTra Dash RT-PCR kit (Toyobo, Osaka, Japan); cDNA
was synthesized by reverse transcription of total RNA (1 lg) using
ReverTra Ace reverse transcriptase and oligo(dT) primer. PCR ampli-
ﬁcation was performed with KOD dash Taq polymerase in a Thermal
Cycler (Eppendorf AG, Hamburg, Germany) for 35 cycles of 10 s at
98 C, 10 s at 53 C, and 30 s at 74 C (for NAPE-PLD) or 22 cycles
of 10 s at 98 C, 10 s at 60 C, and 30 s at 74 C (for GAPDH), using
the following PCR primers: NAPE-PLD, 5 0-CCAGCCATCAGC-
CATGAGGGT-3 0 and 5 0-GGAGCCATCAGCCATGAGGGT-30
[22], and GAPDH, 5 0-ACCACAGTCCATGCCATCAC-3 0 and 5 0-
TCCACCACCCTGTTGCTGTA-3 0 (Toyobo). PCR products were
resolved by 2% agarose gel electrophoresis, visualized by ethidium bro-
mide staining, and quantiﬁed using LAS-3000 image analyzer and
MultiGauge software (FUJIFILM Corporation, Tokyo, Japan).2.7. Assay for the anandamide-degrading enzyme activity
The activity of an anandamide-degrading enzyme, fatty acid amide
hydrolase (FAAH) was measured as described previously [21]. Mem-
brane fractions (20 lg) were mixed with a substrate, [3H]-anandamide
(5 lM, 30000 dpm/nmol) in 50 mM Tris–HCl (pH 9.0) containing
1 mM EDTA in a ﬁnal volume 200 ll, and incubated at 37 C for
30 min. The reaction was terminated by the addition of 400 ll chloro-
form/methanol (1:1, v/v). Then, the mixtures were vortexed for 30 s,
and centrifuged at 5000 · g for 5 min. The upper aqueous layer
(200 ll) containing the degraded product, [3H]-ethanolamine, was col-
lected and subjected to liquid scintillation counting.
2.8. Assay for LPS-binding
RAW264.7 cells (106/ml) were incubated with Alexa488-conjugated
LPS (10 ng/ml) at 37 C for 15 min in the absence or presence of
CAP11 (100 and 1000 ng/ml) or an neutralizing anti-CD14 monoclonal
antibody (4C1, 4 lg/ml) in RPMI1640 containing 10% FCS. Cells were
then washed twice with ice cold PBS, and the LPS-binding was ana-
lyzed by ﬂow cytometry [11].2.9. Statistical analysis
Data are shown as the means ± S.D. Statistical signiﬁcance was
determined by one-way ANOVA with multiple comparison test
(Prism, GraphPad Software, Inc., San Diego, USA), and the results
were considered signiﬁcant at P < 0.05.3. Results
3.1. Production of anandamide
A murine macrophage cell line RAW264.7 is known to pro-
duce anandamide in response to LPS-stimulation [23]. To
investigate the eﬀect of cathelicidin peptide (CAP11) on
anandamide production, we ﬁrst examined the anandamide
production from LPS-stimulated RAW264.7. As shown in
Fig. 1. Eﬀect of CAP11 on the anandamide production from
RAW264.7 cells. RAW264.7 cells were incubated without (Resting)
or with 10 ng/ml LPS (LPS) in the absence or presence of CAP11
(+CAP11) at 37 C for 2 h, and anandamide was measured by DBD-
COCL-labeling and HPLC. Anandamide production is expressed as
fold increase relative to Resting. Data are the means ± S.D. of three
independent experiments. Values are compared between LPS and
Resting or +CAP11. *, P < 0.05; **, P < 0.01.
Fig. 2. Eﬀect of CAP11 on the anandamide-synthesizing enzyme
activity of RAW264.7 cells. RAW264.7 cells were incubated without
(Resting) or with 10 ng/ml LPS (LPS) in the absence or presence of
CAP11 (+CAP11) at 37 C for 2 h. The anandamide-synthesizing
enzyme activity was measured using membrane fractions and expressed
as fold increase relative to Resting. Data are the means ± S.D. of ﬁve
independent experiments. Values are compared between LPS and
Resting or +CAP11. *, P < 0.05.
Fig. 3. Assay for the mRNA expression of N-arachidonyl phospha-
tidylethanolamine hydrolyzing phospholipase D (NAPE-PLD).
RAW264.7 cells were incubated without (Resting) or with 10 ng/ml
LPS (LPS) in the absence or presence of CAP11 (+CAP11) at 37 C for
2 h. The expression of NAPE-PLD was detected using RT-PCR (a)
and expressed as fold change relative to Resting (b). Data are the
means ± S.D. of three independent experiments. Values are compared
between LPS and Resting or +CAP11. *, P < 0.05; ***, P < 0.001.
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production 2.7-fold; anandamide production was signiﬁ-
cantly increased from 3.06 ± 0.91 (Resting) to 8.41 ± 1.64
(LPS) pmol/108 cells (P < 0.01). Of note, 1000 ng/ml CAP11
markedly suppressed the anandamide production to almost
the resting level (P < 0.001), although 100 ng/ml CAP11 hardly
aﬀected the LPS-induced anandamide production.
3.2. Anandamide-synthesizing enzyme activity
To clarify the suppressive eﬀect of CAP11 on anandamide
production, we next investigated the activity of anandamide-
synthesizing enzyme. The activity was measured based on the
release of [3H]-anandamide from [3H]-N-arachidonyl phospha-
tidylethanolamine, using rapid zirconium precipitation method
[20]. As shown in Fig. 2, RAW264.7 cells has a basal ananda-
mide-synthesizing enzyme activity, and LPS slightly but signif-
icantly enhanced the activity (1.3-fold, P < 0.05); the
anandamide-synthesizing enzyme activity was increased from
0.26 ± 0.09 (Resting) to 0.33 ± 0.07 (LPS) nmol/min/mg pro-
tein. In accord with the eﬀect on anandamide production,
1000 ng/ml but not 100 ng/ml CAP11 signiﬁcantly suppressed
the enzyme activity (P < 0.05). Thus, the inhibitory eﬀect of
CAP11 on anandamide production possibly depends on the
suppression of anandamide-synthesizing enzyme activity.
NAPE-PLD was ﬁrst isolated as an N-acylethanolamine
phospholipid-degrading enzyme [24] and later known as an
anandamide-synthesizing enzyme [22]. However, Liu et al.
have recently reported that LPS-stimulated RAW264.7 pro-
duce anandamide through an alternative pathway independent
of NAPE-PLD [25]. To conﬁrm this issue, we examined the
expression of NAPE-PLD mRNA after LPS-stimulation of
RAW264.7 cells and also the eﬀect of CAP11 on the mRNA
expression. Consistent with the previous observation [25], the
expression of NAPE-PLD mRNA was signiﬁcantly downregu-
lated (about 30%) by LPS-stimulation (Fig. 3), which increased
the anandamide production from RAW264.7 cells (Figs. 1 and
2). Furthermore, the LPS-induced downregulation of NAPE-PLD mRNA expression was reversed by 1000 ng/ml but not
100 ng/ml CAP11 (Fig. 3). These observations indicate that
not NAPE-PLD but an alternative anandamide-synthesizing
pathway plays a role in the increased production of ananda-
mide (conversion of NAPE to anandamide) from LPS-stimu-
lated RAW264.7 cells, as previously suggested [25], and that
the suppressive eﬀect of CAP11 on the LPS-induced ananda-
Fig. 4. Eﬀect of CAP11 on the FAAH activity of RAW264.7 cells.
RAW264.7 cells were incubated without (Resting) or with 10 ng/ml
LPS (LPS) in the absence or presence of CAP11 (+CAP11) at 37 C for
2 h. FAAH activity was measured using membrane fractions and
expressed as fold change relative to Resting. Data are the
means ± S.D. of four independent experiments.
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cannot be explained simply by the eﬀect on NAPE-PLD.
3.3. FAAH activity
It is possible that the CAP11-mediated suppression of
anandamide production is due to the enhanced activity of
FAAH, an anandamide-degrading enzyme. Therefore, we
investigated the eﬀect of CAP11 on the FAAH activity. FAAH
activity was measured based on the [3H]-ethanolamine from
[3H]-anandamide. As shown in Fig. 4, in contrast to the eﬀects
on the synthetic enzyme, the FAAH activity was not aﬀected
by not only LPS but also CAP11 (0.96–1.1-fold change of
the resting level); the FAAH activity was 0.12 ± 0.06 nmol/
min/mg protein in resting cells, and was almost the same inFig. 5. Eﬀect of CAP11 on the binding of LPS to RAW264.7 cells.
RAW264.7 cells were incubated with 10 ng/ml Alexa488-conjugated
LPS in the absence (Control) or presence of CAP11 (+CAP11) or an
neutralizing anti-CD14 antibody (+aCD14) at 37 C for 15 min, and
then the LPS-binding was analyzed by ﬂow cytometry. The LPS-
binding is expressed as a percentage of Control (mean ﬂuorescence
intensity of 0.47 ± 0.06). Data are the means ± S.D. of three indepen-
dent experiments. Values are compared between Control and +CAP11
or +aCD14. ***, P < 0.001.LPS-stimulated or CAP11-treated cells. Thus, the CAP11-
mediated suppression of anandamide production is unlikely
to be due to the change in the activity of an anandamide-
degrading enzyme FAAH.3.4. LPS-binding to RAW264.7 cells
CAP11 has a potent LPS-neutralizing activity and protects
mice from endotoxin shock [11]. To clarify the suppressive ef-
fect of CAP11 on anandamide production, we ﬁnally examined
the eﬀect of CAP11 on LPS-binding to RAW264.7 cells using
Alexa488-conjugated LPS by ﬂow cytometry. As shown in
Fig. 5, in concordance with the eﬀects on the anandamide pro-
duction and NAPE-PLD activity, 1000 ng/ml but not 100 ng/
ml CAP11 inhibited the LPS-binding. In addition, we con-
ﬁrmed that the LPS-binding was almost completely inhibited
by a neutralizing anti-CD14 monoclonal antibody (4 lg/ml)
[17], suggesting that CAP11 inhibits the CD14-mediated
LPS-binding to RAW264.7 cells.4. Discussion
Endotoxin shock is severe and abnormal conditions that are
induced during serious infections with Gram-negative bacteria
[1]. Endotoxin shock could also occur in the process of anti-
biotic therapy for the underlying bacterial infections in septic
syndrome. In this context, some antibiotics are known to kill
the bacteria but stimulate the release of LPS from outer mem-
brane of dying bacteria, thereby provoking endotoxin shock
[26]. Thus, a novel drug that suppresses the actions of LPS
could be utilized for a reasonable adjunctive therapy against
endotoxin shock or sepsis caused by Gram-negative bacteria.
CAP11, a cathelicidin peptide isolated from guinea pig has a
strong antibacterial against Gram-positive and -negative bac-
teria [14,16]. CAP11 also exhibits a potent LPS-neutralizing
activity, and rescues experimental animals from endotoxin
shock [11]. Mononuclear phagocytes have been reported to
produce anandamide in vitro upon stimulation with LPS
[23]. Thus, in this study, to elucidate the protective mechanism
of CAP11 for endotoxin shock, we evaluated the action of
CAP11 on the production of anandamide, a key mediator of
endotoxin shock in vitro using RAW264.7, a murine macro-
phage cell line.
LPS-stimulation induced the production of anandamide
from RAW264.7 cells, accompanied with the enhanced
anandamide-synthesizing enzyme activity, which is likely to
depend on an alternative anandamide-synthesizing pathway
rather than NAPE-PLD [25]; however, the activity of an
anandamide-degrading enzyme (FAAH) was not aﬀected by
LPS-stimulation. Of importance, 1000 ng/ml CAP11 almost
completely suppressed the LPS-induced anandamide produc-
tion and the increase of anandamide-synthesizing enzyme
activity, whereas 100 ng/ml CAP11 aﬀected neither the
anandamide production nor anandamide-synthesizing enzyme
activity. Consistent with these actions, 1000 ng/ml but not
100 ng/ml CAP11 abrogated the LPS-binding to CD14 on
RAW264.7 cells. These observations apparently indicate that
CAP11 inhibits the binding of LPS to CD14-positive mononu-
clear phagocytes, thereby suppressing the increase of an
anandamide synthesizing enzyme activity and the production
of anandamide from the cells.
144 T. Murakami et al. / FEBS Letters 581 (2007) 140–144In the case of endotoxin shock patients, serum levels of
anandamide are increased for three or four times of those in
healthy volunteers [27]. Furthermore, anandamide has been
proposed to exert cardiovascular actions as a contributor to
endotoxin shock-induced hypotension [2], which results in cir-
culating failure and multiple organ impairment in Gram-nega-
tive bacterial sepsis. The present study has demonstrated that
CAP11 has a potential to suppress anandamide production
based on its LPS-neutralizing activity. We previously revealed
that CAP11 has a potent antibacterial activities against Gram-
positive and -negative bacteria [14,16] and inhibits the produc-
tion of cytokines from mononuclear phagocytes, which
mediate the development of endotoxin shock [11]. Thus,
CAP11 could be a promising candidate for adjunctive therapy
in Gram-negative bacterial sepsis, since CAP11 could be
expected not only to overcome the underlying bacterial infec-
tions but also to block the LPS-triggered inﬂammatory reac-
tions by suppressing the binding of LPS to CD14-positive cells.
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